Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBCBSNM biomarker testing coverage update | OpenPay…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - New MexicoPolicy RPLAB011

    Biomarker Testing for Autoimmune Rheumatic Disease

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - New Mexico Policy RPLAB011 alerts

    Get alerted when Policy RPLAB011 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Reimbursement criteria for laboratory biomarker testing used to diagnose, evaluate, or monitor autoimmune rheumatic diseases for Blue Cross Blue Shield - New Mexico members and participating providers.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyBiomarker Testing for Autoimmune Rheumatic Disease
    Policy CodePolicy RPLAB011
    Change TypeRevisions to reimbursement information and added/updated procedure codes
    Effective DateSep 4, 2026
    Last ReviewSep 4, 2026
    Next Review Date
    Key ActionProviders must submit accurate documentation and valid coding; claims may require additional documentation upon request.
    SourceLink
    POLICY UPDATE CHANGES

    Document updated with literature review and Reimbursement Information edits; items #11, #12, #13 were edited for clarity and 'Tissue Specific Markers for Early Diagnosis of Sjögren's Disease' was added to #13.

    Reimbursement Information edited for clarity on allowed frequency of biomarker testing and new non-reimbursable items added (e.g., Seronegative Rheumatoid Arthritis Profile; aisle® DX Disease Activity Index; Early Sjögren's Syndrome Profile).

    Statement added: for individuals with painful and swollen joints and clinical suspicion of RA, testing for RF and/or anti-CCP may be reimbursable once per lifetime in individuals with stable symptoms; repeat testing only if significant change occurs.

    Policy clarified that serum biomarker panel testing for RA disease management (e.g., Vectra DA, PrismRA) is not reimbursable; prior related policy CPCPLAB039 addressed Vectra DA.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    once + up to 2allowed ANA screening frequency
    ≤4/yrdsDNA monitoring
    multiple namednonreimbursable panels
    ≈7procedure codes listed
    >=3new/revised codes
    multiplepolicy history entries

    Coverage Criteria for Biomarker Testing

    COVERAGE CRITERIA

    Coverage determinations for antibody and biomarker testing in autoimmune rheumatic disease.

    ALL of the following

    • Once during initial workup.
    • Up to two additional tests per lifetime if new or more severe signs or symptoms of an autoimmune disease develop.
    Reimbursable: For individuals with an abnormal, raised ANA titer and clinical correlation with the appropriate autoimmune disorder, extractable nuclear antigen (ENA) panel testing of specific autoantibodies may be reimbursable.

    ALL of the following

    • Once during initial workup.
    • If initial testing did not result in a diagnosis of RA, up to two additional tests per lifetime if symptoms persist or additional symptoms of RA develop.
    Reimbursable: For individuals with an initial positive ANA test and a diagnosis of systemic autoimmune rheumatic disease, testing of dsDNA may be reimbursable up to four times per year.

    Condition-specific antibody testing (when indicated)

    • Testing for anti-Jo-1 in a unique clinical subset of myositis.
    • Testing for anti-SSA in the setting of lupus or Sjögren's syndrome.
    Not reimbursable: Monitoring of disease using ANA testing or ANA titers.
    Not reimbursable: ANA and/or ENA testing for individuals without symptoms suggestive of an autoimmune disorder (including during wellness visits or general exams without abnormal findings).
    Not reimbursable: Testing of specific antibodies in the absence of a positive ANA test except as noted for specific condition-driven exceptions.
    Not reimbursable: Serum biomarker panel testing designed to diagnose, prognose, or monitor disease (examples include but are not limited to: Vectra, PrismRA, AVISE Lupus, AVISE CTD, AVISE SLE Monitor, AVISE SLE prognostic, aisle® DX Disease Activity Index, Early Sjögren's Syndrome Profile, Tissue Specific Markers for Early Diagnosis of Sjögren's Disease).
    Not reimbursable: Serum biomarker panels for diagnosis or management of RA not described above (e.g., Seronegative Rheumatoid Arthritis Profile).

    Extracted coverage-related statements

    Summarized reimbursement positions and changes from policy history.

    Rheumatoid factor and/or anti-CCP testing frequency update: For individuals with painful and swollen joints and clinical suspicion of RA, RF and/or anti-CCP testing may be reimbursable once per lifetime in individuals with stable symptoms; repeat testing only if a significant change in symptoms occurs (policy history additions and clarifications).
    Non-reimbursable panels update: Serum biomarker panel testing for RA disease management (e.g., Vectra DA, PrismRA) and specified proprietary panels (for example: Seronegative Rheumatoid Arthritis Profile, aisle® DX Disease Activity Index, Early Sjögren's Syndrome Profile) are explicitly listed as not reimbursable; several items in #11-#13 were edited for clarity and additional named examples were added over time.
    Coding and references update: Policy history documents addition of multiple procedure codes (including 86200, 86340, 86341 and later 0446U, 0447U, 0521U, 0522U) and revisions to references and reimbursement language across several updates.

    Procedure Codes and Testing Frequency

    Procedure codes referenced in policyCPT
    81490AUTOIMMUNE RA ALYS 12 BMRK.
    81599UNLISTED MAAA.
    86038ANTINUCLEAR ANTIBODIES.
    86039ANTINUCLEAR ANTIBODIES (ANA).
    86200CCP ANTIBODY.
    86225DNA ANTIBODY NATIVE.
    86235NUCLEAR ANTIGEN ANTIBODY.
    86430RHEUMATOID FACTOR TEST QUAL.
    86431RHEUMATOID FACTOR QUANT.
    0039UDNA ANTB 2STRAND HI AVIDITY.
    1–10 of 16
    1/2
    codes referenced in policy historymixed
    0522UNew code added per policy history
    0446UCode added previously (policy history)
    0447UCode added previously (policy history)
    0521UCode added previously (policy history)
    86200CCP ANTIBODY (added to policy history)
    86340Immunoassay; analyte (added to policy history)
    86341Immunoassay; analyte (added to policy history)
    inv-05: ANA testing lifetime allowances
    AllowanceANA screening reimbursable once during initial workup for individuals with signs or symptoms of autoimmune disease
    Additional lifetime testsUp to two additional ANA tests per lifetime if new or more severe signs or symptoms of autoimmune disease develop
    Not for monitoringMonitoring disease with ANA testing or ANA titers is not reimbursable
    inv-06: RF/anti-CCP testing allowance for RA workup
    Initial workupRF and/or anti-CCP testing reimbursable once during initial workup for individuals with painful and swollen joints suggestive of rheumatoid arthritis (RA)
    Additional lifetime tests if nondiagnostic

    Documentation, Billing, and Reimbursement Notices

    Documentation Required

    Submit accurate documentation and valid coding; respond to claim review requests

    Providers must submit accurate documentation of services performed and submit claims using valid, industry-standard code sets and combinations. Claims are subject to code edit protocols and review; upon request, providers should supply any additional documentation the Plan requests.

    • Use HIPAA-approved code sets and follow Uniform Billing, AMA CPT, HCPCS, ICD-10-CM/PCS, NDC, and CMS coding guidance.
    • Claims may be reviewed against benefit terms, provider contract language, medical and reimbursement policies, and coding software logic.
    • Be prepared to provide additional documentation upon request to support medical necessity and coding.
    Note

    Account for reimbursement edits and added/updated codes from policy history

    Review the Policy History for recent reimbursement edits and newly added procedure codes; reimbursements, allowed frequencies, and non-reimbursable tests have been updated in the policy history entries.

    Definitions and Non-Reimbursable Tests

    inv-11: Antinuclear antibody (ANA) screening
    DefinitionAntinuclear antibody (ANA) screening: reimbursable once during initial workup for individuals with signs or symptoms of autoimmune disease
    Limited repeatsUp to two additional lifetime ANA tests if new or more severe signs or symptoms develop
    ExclusionsANA testing for monitoring or for asymptomatic individuals (including wellness visits) is not reimbursable
    inv-12: Proprietary or multi-biomarker serum panels
    Nonreimbursable panels (examples)Serum biomarker panels designed to manage RA (e.g., Vectra, PrismRA) are not reimbursable
    Nonreimbursable for SLE/CTDCell-bound complement activation products (e.g., AVISE Lupus) and serum biomarker panels (e.g., AVISE CTD, AVISE SLE Monitor) designed to diagnose, prognose, or monitor SLE/CTD are not reimbursable

    Policy Revision History and Material Changes

    2024-04-29policy_update

    Document updated with literature review; added statement that RF and/or anti-CCP testing may be reimbursable once per lifetime for individuals with stable symptoms with repeat testing only if significant change occurs, and codes 86200, 86340, 86341 were added.

    2023-11-01policy_update

    Document updated with literature review; reimbursement information revised to clarify 'Once per lifetime in individuals with stable symptoms' and 'Repeat testing only if a significant change in symptoms occurs' were added to policy statements.

    2026-09-04effective_date
    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyBiomarker Testing for Autoimmune Rheumatic Disease
    Policy CodePolicy RPLAB011
    Change TypeRevisions to reimbursement information and added/updated procedure codes
    Effective DateSep 4, 2026
    Last ReviewSep 4, 2026
    Next Review Date
    Key ActionProviders must submit accurate documentation and valid coding; claims may require additional documentation upon request.
    SourceLink
    On This Page
    Coverage Criteria for Biomarker TestingProcedure Codes and Testing FrequencyDocumentation, Billing, and Reimbursement NoticesDefinitions and Non-Reimbursable TestsPolicy Revision History and Material Changes
    If initial testing did not result in a diagnosis of RA, up to two additional RF/anti-CCP tests per lifetime if symptoms persist or additional symptoms of RA develop
    Guidance from policy historyPolicy history also states RF/anti-CCP testing may be reimbursable once per lifetime in individuals with stable symptoms; repeat only if significant change in symptoms occurs
    inv-07: dsDNA testing frequency after diagnosis
    Post-diagnosis frequencydsDNA testing reimbursable up to four times per year for individuals with an initial positive ANA test and a diagnosis of systemic autoimmune rheumatic disease
    ContextApplies to individuals with diagnosis and prior positive ANA
    PurposeIntended for monitoring in established systemic autoimmune rheumatic disease (per reimbursement information)
    inv-08: testing_frequency_guidance
    RF/anti-CCP single-lifetime guidancePolicy history specifies RF/anti-CCP testing may be reimbursable once per lifetime in individuals with stable symptoms
    Repeat criteriaRepeat RF/anti-CCP testing only if a significant change in symptoms occurs or if initial testing was nondiagnostic and symptoms persist
    Clinical triggerSignificant change in clinical presentation (new/worsening symptoms) required to justify repeat testing
    • Note newly added procedure codes in policy history (examples added: 86200, 86340, 86341, 0446U, 0447U, 0521U, 0522U).
    • Recognize that reimbursement information was revised for allowed testing frequencies (e.g., RF/anti-CCP frequency clarifications, ANA frequency guidance) and that multiple proprietary biomarker panels were added to the non-reimbursable list.
    • Policy history entries include dates and descriptions of these edits—providers should consult the policy history when submitting claims for affected tests.
    Policy history notePolicy history clarifies these panel exclusions and lists additional named nonreimbursable panels added in recent updates
    inv-13: multi-biomarker disease activity panel
    Example panels for RASerum biomarker panel testing for RA (e.g., Vectra DA, PrismRA) is identified as not reimbursable
    PurposeThese panels are designed to assess disease activity/management and are excluded from reimbursement
    Cross-referencePrior related policy CPCPLAB039 addressed Vectra DA; current policy reiterates nonreimbursable stance
    inv-14: non-reimbursable panels
    Named non-reimbursable testsExamples listed as not reimbursable include Seronegative Rheumatoid Arthritis Profile and aisle® DX Disease Activity Index
    Additional named exclusionsEarly Sjögren's Syndrome Profile and other specified proprietary panels (listed in policy #13) are not reimbursable
    ScopePolicy explicitly lists multiple proprietary or indexed panels that are excluded from reimbursement when designed to diagnose, prognose, or monitor disease
    Latest

    Policy RPLAB011 effective date published.